Routine use of the Impella CP microaxial flow pump did not improve outcomes and may have contributed to deaths among patients undergoing high-risk percutaneous coronary intervention (PCI), according ...

NEW ORLEANS, LA—The Impella CP percutaneous left ventricular assist device (pLVAD) does not reduce major adverse events when used in the setting of high-risk PCI, according to the CHIP-BCIS3 trial.

Add Yahoo as a preferred source to see more of our stories on Google. Johnson & Johnson's Impella CP heart pump in an illustration of the heart. Johnson & Johnson’s Impella heart pump failed to lower ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ benefits, spanning specific cases in patients with blockages in their coronary ...

The Abiomed Mobile Learning Lab visited the Springfield Regional Medical Center to educate its heart care team on the Impella device and give a hands-on simulation of implanting the device. The ...